Recombinant Protein Production with Prokaryotic and Eukaryotic Cells. A Comparative View on Host Physiology - Selected articles from the Meeting of the EFB Section on Microbial Physiology, Semmering, Austria, 5th-8th October 2000 (Paperback, Softcover reprint of hardcover 1st ed. 2001)


More then 20 years have passed now since the first recombinant protein producing microorganisms have been developed. In the meanwhile, numerous proteins have been produced in bacteria, yeasts and filamentous fungi, as weIl as higher eukaryotic cells, and even entire plants and animals. Many recombinant proteins are on the market today, and some of them reached substantial market volumes. On the first sight one would expect the technology - including the physiology of the host strains - to be optimised in detail after a 20 year's period of development. However, several constraints have limited the incentive for optimisation, especially in the pharmaceutical industry like the urge to proceed quickly or the requirement to define the production parameters for registration early in the development phase. The additional expenses for registration of a new production strain often prohibits a change to an optimised strain. A continuous optimisation of the entire production process is not feasible for the same reasons.

R5,864

Or split into 4x interest-free payments of 25% on orders over R50
Learn more

Discovery Miles58640
Mobicred@R550pm x 12* Mobicred Info
Free Delivery
Delivery AdviceShips in 10 - 15 working days



Product Description

More then 20 years have passed now since the first recombinant protein producing microorganisms have been developed. In the meanwhile, numerous proteins have been produced in bacteria, yeasts and filamentous fungi, as weIl as higher eukaryotic cells, and even entire plants and animals. Many recombinant proteins are on the market today, and some of them reached substantial market volumes. On the first sight one would expect the technology - including the physiology of the host strains - to be optimised in detail after a 20 year's period of development. However, several constraints have limited the incentive for optimisation, especially in the pharmaceutical industry like the urge to proceed quickly or the requirement to define the production parameters for registration early in the development phase. The additional expenses for registration of a new production strain often prohibits a change to an optimised strain. A continuous optimisation of the entire production process is not feasible for the same reasons.

Customer Reviews

No reviews or ratings yet - be the first to create one!

Product Details

General

Imprint

Springer

Country of origin

Netherlands

Release date

December 2010

Availability

Expected to ship within 10 - 15 working days

First published

2001

Editors

, , , , , , , ,

Dimensions

235 x 155 x 21mm (L x W x T)

Format

Paperback

Pages

400

Edition

Softcover reprint of hardcover 1st ed. 2001

ISBN-13

978-90-481-5756-3

Barcode

9789048157563

Categories

LSN

90-481-5756-0



Trending On Loot